The moment a laboratory instrument produces a result is not the moment that result becomes clinically useful. Between an analyzer generating a number and a physician acting on that number lies a sequence of steps that are as consequential to patient safety as any part of the testing process that preceded them. Those steps collectively constitute the post analytical phase in laboratory testing, and they determine whether an accurate measurement becomes a correct clinical decision or whether it becomes a missed diagnosis, a delayed treatment, or a harmful intervention.
The total testing process in clinical laboratory medicine is conventionally divided into three phases: pre-analytical, analytical, and post-analytical. A large body of published literature has established that pre-analytical errors, occurring in specimen collection, labeling, transport, and receipt, account for approximately 46 to 68 percent of all laboratory errors. The analytical phase, despite being the most technologically sophisticated, contributes the smallest share of errors, typically 7 to 13 percent, because of the precision built into modern automated analyzers and their quality control systems. Post-analytical errors, occurring after the specimen has been analyzed and a result produced, account for between 18 and 47 percent of total errors depending on the study and definition applied.
What those percentages conceal is that post-analytical errors carry a disproportionate potential for clinical harm. A 2023 cohort study of 2,428 hospitalized adults published in JAMA Internal Medicine found that patient assessment problems, including delay in considering a diagnosis and failure to recognize complications, and problems with test ordering and interpretation, including erroneous clinician interpretation of test results, were identified as the primary improvement opportunities. In a voluntary incident report analysis published in the literature, while post-analytical errors represented 8.0 percent of reported laboratory errors, severe clinical impact occurred in 28 percent of post-analytical phase failures, a rate comparable to that of analytical errors and substantially higher than the clinical impact rate of pre-analytical failures. This pattern reflects the nature of post-analytical phase errors: they occur at the interface between the laboratory’s output and the clinician’s decision, which is precisely where patient management is shaped.
What the Post Analytical Phase Actually Includes
The post-analytical phase encompasses every process that occurs from the moment a result is ready for release through the moment it is interpreted by the clinician and acted upon. This is broader than it might initially appear, and its boundaries extend further than the laboratory’s walls.
Within the laboratory, post-analytical processes include result validation before release, autoverification, delta check review, critical value identification and notification, report generation and formatting, transmission of results to the ordering system or electronic health record, storage of specimens for potential repeat testing, and the generation of interpretive comments where appropriate.
Beyond the laboratory, the post-analytical phase extends into what some authors call the post-post-analytical phase: the clinician’s receipt of results, the accuracy of result interpretation, the decision about what clinical action to take based on the result, and whether that action is actually carried out. ISO 15189:2022, the international standard for medical laboratory quality, frames post-examination requirements to cover both the laboratory’s reporting responsibilities and the interpretive assistance it provides to clinical users. This framing acknowledges that the laboratory’s obligation to the patient does not end when the result leaves the LIS. Errors in clinical interpretation of technically correct results constitute a documented category of diagnostic failure that laboratory quality systems are increasingly expected to address through educational consultation, interpretive comment policies, and active communication with ordering providers.
According to a PMC-published analysis of post-analytical process management under ISO 15189, approximately 5 percent of laboratory-related errors stem from result misinterpretation, and this misinterpretation causes 33 percent of delays, diagnostic errors, or missed diagnoses. The same source notes that other analyses have found that errors in interpretation of analytical results account for 37 percent of errors in the diagnostic process, second only to errors in the test request itself. These are not small numbers, and they situate the post-analytical phase as a domain where laboratory medicine and clinical medicine must function as genuine partners.
Result Validation: The Last Line of Defense Before Release
Before any result reaches a clinician, it must be reviewed against a set of criteria that confirm it is analytically valid and clinically plausible. This review process, called result validation or result verification depending on the framework used, is required by ISO 15189 and constitutes the core of laboratory post-analytical quality control.
Manual validation, in which a laboratory scientist reviews each result individually, was the historical standard and remains appropriate for complex or unusual results. As laboratory test volumes have grown into the millions of specimens per year in high-throughput settings, manual validation of every result has become logistically impractical. Autoverification, the automated release of results using predefined rules encoded in the laboratory information system, has become the practical solution for high-volume routine testing. A well-designed autoverification system applies a multi-layered set of rules to each result before releasing it: it checks whether the result falls within the instrument’s analytical measurement range, whether the internal quality control run for that shift passed, whether any instrument flags are present, whether serum or plasma interference indices indicate hemolysis, lipemia, or icterus that might compromise the result’s validity, whether the result falls within defined critical value limits requiring immediate notification, and whether any delta check against the patient’s previous results triggers a review.
A survey published in ResearchGate found that among laboratories implementing autoverification, 7 out of 13 reported autoverification rates between 20 and 50 percent of all results, and 10 out of 13 reported that the introduction of autoverification significantly reduced turnaround time, typically by 20 to 25 percent, particularly for biochemistry tests. The turnaround time gains of autoverification are not merely operational conveniences. For time-critical results in emergency medicine, intensive care, and acute cardiac care, getting a validated result to the clinician faster translates directly into faster treatment initiation and better patient outcomes.
The Delta Check: Catching Errors That Quality Control Misses
One of the most important tools in post-analytical validation is the delta check, a comparison of a patient’s current result against their most recent previous result for the same analyte. The underlying principle is that most physiological variables change gradually over time. If a patient’s serum sodium was 139 mmol/L two days ago and appears as 158 mmol/L today, the plausibility of that change in the clinical context must be assessed. Occasional dramatic shifts are clinically real and represent important diagnostic findings. But similar patterns also arise when a specimen is mislabeled with the wrong patient identifier, a far more common occurrence than many clinicians appreciate.
Delta checks serve two distinct quality functions: they detect potential specimen identification errors, where a current result belongs to a different patient than the one whose history is being compared, and they detect analytical errors affecting method performance, such as calibration drift that shifts all results systematically in one direction. Studies using reference change value calculations for delta check design, which incorporate known biological variation and analytical imprecision to set limits based on what degree of change is physiologically plausible, have provided a more evidence-based framework for this tool than the historically arbitrary fixed limits used in many laboratories.
In a validation study examining delta check performance, 1.35 percent of all test results failed the reference change value delta check and required manual verification. Of those, 0.12 percent were true positives indicating actual laboratory error, while 1.23 percent were false positives with no underlying error that nonetheless required manual review. This ratio illustrates both the value of the delta check, it successfully flags genuine errors, and its main challenge: alarm fatigue from a high rate of false positives can desensitize laboratory staff to genuine alerts, a phenomenon that must be managed through careful calibration of delta check thresholds and ongoing evaluation of their performance.
A survey of Croatian medical biochemistry laboratories found that 59 percent of laboratories did not use delta check at all, and only 20 percent used reflex or reflective testing, despite both practices being recommended in national guidelines. These findings, consistent with patterns observed in other countries, indicate that post-analytical quality tools are inconsistently deployed even in settings where pre-analytical and analytical quality programs are well established.
Critical Value Notification: When Speed Determines Outcome
Among all post-analytical processes, critical value notification carries the highest direct clinical stakes. A critical value is a laboratory result at such variance from normal that it represents a life-threatening physiological state requiring immediate intervention. Severe hyperkalemia, critically low glucose, markedly elevated troponin in a patient not yet known to have cardiac disease, extremely prolonged coagulation times, and markedly low hemoglobin in an actively bleeding patient are examples of results that require not just release into the electronic health record but active verbal communication to a responsible clinician within a defined, short timeframe.
The requirement for critical value notification policies, including a documented list of critical values, a defined communication timeframe, and a verified read-back process, is codified under CLIA regulations in the United States and required by accrediting bodies including the College of American Pathologists and the Joint Commission. ISO 15189:2022 similarly requires laboratories to define which results require urgent notification, establish procedures for timely communication, and document that notification occurred along with the identity of the recipient.
The clinical consequences of critical value notification failures are documented in patient safety literature. Pennsylvania Patient Safety Advisory reports have described patients whose pre-procedural critical electrolyte values were not communicated before they entered the cardiac catheterization laboratory, resulting in preventable adverse cardiac events. In these cases, the laboratory performed its analytical function correctly. The failure occurred entirely in the post-analytical phase.
Quantitative data on notification performance are available. A study evaluating critical result notification at a tertiary care hospital found that out of 390,000 investigations over a six-month period, 0.5 percent generated critical alerts. Of those critical alerts, the success rate of notification within one hour was 86.8 percent, meaning 10.7 percent of critical results failed to reach the responsible clinician within the specified timeframe. The causes of unsuccessful reporting included outpatient requests where no in-facility contact was available, and delayed intimation due to patient discharge or transfer. Published literature indicates that un-notified critical alerts across settings range from 0.1 to 10.2 percent of critical results generated, a range wide enough to signal that notification systems vary substantially in their reliability and that no institution should assume the process is working without measuring it.
Reference Intervals and Interpretive Assistance
A laboratory result is clinically meaningless without a context for interpretation. That context is provided by reference intervals, the ranges of values observed in a defined healthy reference population, and by clinical decision limits, the thresholds above or below which specific clinical actions are recommended or required. Both are post-analytical constructs: the measurement is analytical, but the interpretive framework attached to it is post-analytical.
ISO 15189:2022 requires laboratories to define, document, and periodically review their biological reference intervals and clinical decision limits, ensuring they are appropriate for the populations they serve. This requirement is not trivial. Reference intervals established in one demographic population may not apply to another. Pediatric and geriatric populations have different reference ranges for many analytes than healthy adults of working age. Sex-specific differences exist for creatinine, hemoglobin, ferritin, and many other analytes. A result that appears normal against an inappropriate reference interval may represent significant pathology in the patient being tested, and a result that appears abnormal against an overly broad reference interval may generate unnecessary clinical concern.
Interpretive comments, text added to laboratory reports that explain the clinical significance of a result, its limitations in particular clinical contexts, or recommendations for follow-up testing, extend the laboratory’s post-analytical contribution further. When a hemolyzed specimen limits the reliability of a potassium result, an interpretive comment informs the clinician rather than leaving them to act on a potentially falsely elevated value. When a mildly elevated PSA could reflect benign prostatic hyperplasia or a recent prostate biopsy procedure rather than malignancy, a comment contextualizing the result supports more considered clinical decision-making. According to PMC-published guidance on post-analytical process management under ISO 15189, the scope of post-analytical quality indicators includes reference intervals, cut-off points, interpretive comments, reflex tests triggered automatically by algorithm, and reflective tests added by a laboratory professional considering the clinical context, all of which represent the laboratory’s active contribution to ensuring that its analytical output becomes clinically actionable.
Turnaround Time as a Post Analytical Quality Indicator
Turnaround time, the elapsed interval from specimen receipt in the laboratory to result availability for the ordering provider, is the most universally tracked post-analytical quality indicator, and with good reason. The clinical value of a laboratory result is time-dependent in ways that vary dramatically by test type and clinical setting. A complete blood count result needed to guide whether a patient receives blood transfusion before emergency surgery carries a different urgency than a HbA1c ordered for outpatient diabetes monitoring. A troponin result in a patient with acute chest pain has a clinical half-life measured in minutes; the same test ordered as part of a routine cardiac workup can wait hours without clinical consequence.
ISO 15189:2022 requires that laboratories establish turnaround time goals for different test categories, monitor actual performance against those goals using defined quality indicators, and act on deviations when performance falls below the established standard. The Croatian survey of post-analytical quality management found that in 34 percent of surveyed laboratories, turnaround time and critical value reporting were the two most frequently monitored post-analytical quality indicators, consistent with their direct connection to patient care outcomes. A study using autoverification data found that introducing autoverification reduced turnaround time by 20 to 25 percent for biochemistry tests, generating faster result delivery with no compromise to result validity.
Turnaround time failures generate measurable clinical consequences. Delayed potassium results slow the management of cardiac arrhythmias. Delayed lactate and procalcitonin results delay the activation of sepsis protocols. Delayed blood culture sensitivity results prolong empiric antibiotic therapy when targeted therapy would be both more effective and less likely to contribute to antimicrobial resistance. Tracking and reducing post-analytical delay is therefore not a laboratory performance metric in isolation. It is a patient safety metric with measurable downstream effects on outcomes.
The Human Interface: Where Laboratory Meets Clinical Medicine
Everything described above operates within the laboratory’s sphere of control or at the laboratory-clinician boundary. But the final and arguably most consequential step of the post-analytical phase sits entirely outside laboratory control: the clinician’s interpretation and clinical action.
A result correctly produced, properly validated, promptly delivered, and accurately contextualized can still fail to improve a patient’s outcome if the recipient does not recognize its significance, does not link it to the correct patient, or does not act on it within an appropriate timeframe. This reality positions the post-analytical phase not as a laboratory problem to be solved by better technology alone, but as an interface problem requiring ongoing communication, education, and feedback between laboratories and the clinical teams they serve.
Establishing regular consultation between laboratory professionals and ordering clinicians, providing unit-specific feedback on test utilization and result interpretation patterns, designing reports that are unambiguous rather than technically complete but clinically opaque, and developing targeted educational resources for high-stakes tests with complex interpretive requirements are all practices that high-functioning laboratory medicine programs deploy to reduce the clinical impact of post-analytical failures.
The post-analytical phase is where laboratory medicine proves its clinical value. Accurate measurements that never reach the right clinician, in time, in a form that enables correct interpretation, represent a form of waste that costs more than reagents and labor. They cost patients the accurate, timely diagnosis that laboratory medicine exists to provide.
Conclusion
The post analytical phase in laboratory testing is the bridge between measurement and medicine. It begins the moment a result is ready for review and ends only when a clinician has received, interpreted, and acted on that result appropriately. The processes that constitute it, result validation, autoverification, delta checking, critical value notification, interpretive comment generation, turnaround time monitoring, and the communication infrastructure connecting laboratories to clinical teams, determine whether the analytical accuracy achieved in the laboratory translates into diagnostic accuracy at the bedside.
Post-analytical errors account for 18 to 47 percent of total laboratory errors and carry a disproportionate potential for clinical harm. The tools to reduce them exist: validated autoverification systems, evidence-based delta check protocols, standardized critical value notification procedures with documented read-back, reference intervals appropriate to the patient population, and regular collaboration between laboratory professionals and clinicians. What is required is the organizational commitment to implement and monitor them systematically, and the recognition that laboratory quality does not end when the analyzer produces its result.
Bio-Reach is a non-profit organization dedicated to advancing Laboratory Medicine through advocacy, education, and global collaboration. To learn more or get involved, visit bio-reach.org.
